Elicera Therapeutics have announced the publication of a scientific article describing the mechanism-of-action of the company’s universal CAR T-cell enhancement technology platform iTANK in Nature Biomedical Engineering.
Proof-of-concept data presented in the publication also indicate that the iTANK-platform is universally compatible with other CAR T-cell therapies, states the company in a press release. The iTANK-platform is intended to counteract two of the major challenges CAR T-cell therapies face in the treatment of solid tumors: antigen heterogeneity and a hostile tumor microenvironment.
“I am thrilled that scientific information and data about the iTANK-platform have been published in one of the highest ranked (impact factor 25,7) and most prestigious journals within the field of biomedical engineering. The publication is an important external validation of the iTANK technology platform and the science behind its ability to create a multi-targeted attack on solid tumors. A CAR T-cell therapy for treatment of solid tumors has yet to be approved, so this is an important step forward in realizing this opportunity,” says Jamal El-Mosleh, CEO of Elicera.